This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Agenus To Present At OneMedForum San Francisco 2013

LEXINGTON, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 6 th Annual OneMedForum San Francisco 2013, which will be held at the Sir Francis Drake Hotel in San Francisco.

Dr. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview on Tuesday, January 8 th at 9:40 am PST in the Franciscan Room.

Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon ® adjuvant 1 is being studied in clinical trials for 17 vaccine indications. They include:
  • Phase 3: GSK's RTS,S for malaria 2
  • Phase 3: GSK's MAGE-A3 for non-small cell lung cancer 2
  • Phase 3: GSK's MAGE-A3 for melanoma 2
  • Phase 3: GSK's Zoster Herpes for shingles 2
  • Phase 2: Janssen's ACC-001 for Alzheimer's disease

Agenus pipeline programs include:
  • Phase 2: Prophage Series G-100 for newly diagnosed glioma
  • Phase 2: Prophage Series G-200 for recurrent glioma
  • Phase 2 : HerpV (contains QS-21 Stimulon) for genital herpes

Saponin Platform: QS-21 Stimulon ® Adjuvant

Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.

Heat Shock Protein Platform: Prophage Series G

The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two different settings of glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with an average survival of six to 14 months.

Heat Shock Protein Platform: Recombinant Series HerpV                                                                                                        

HerpV is the most advanced HSV-2 vaccine currently in clinical development for the treatment of genital herpes. A Phase 2 study measuring the effect of vaccination on viral shedding in individuals infected with HSV-2 is underway. Data results for this study are anticipated in Q4'13. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into the clinical benefit of a reduction in recurrent outbreaks.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,739.69 +267.32 1.62%
S&P 500 1,982.71 +31.35 1.61%
NASDAQ 4,773.79 +66.0150 1.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs